Drug Profile

SCO 006

Alternative Names: SCO-006

Latest Information Update: 28 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Developer SCOHIA PHARMA
Class Antineoplastics; Hyperphosphataemia therapies
Mechanism of Action Phosphate transport protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Ovarian cancer
No development reported Hyperphosphataemia

Most Recent Events

28 Aug 2023 No recent reports of development identified for preclinical development in Hyperphosphataemia in Japan (PO)
10 Mar 2023 Preclinical trials in Ovarian cancer in Japan (PO) (SCOHIA PHARMA pipeline, March 2023)
10 Mar 2023 Pharmacodynamics data from a preclinical trial in Hyperphophataemia released by SOCHIA PHARMA (SOCHIA PHARMA pipeline, March 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com